EP1786408A1 - Verwendung eines selektiven östrogenrezeptormodulators zur herstellung eines pharmazeutischen präparates zur verwendung in einem verfahren für die behandlung oder vorbeugung von androgenmangel - Google Patents

Verwendung eines selektiven östrogenrezeptormodulators zur herstellung eines pharmazeutischen präparates zur verwendung in einem verfahren für die behandlung oder vorbeugung von androgenmangel

Info

Publication number
EP1786408A1
EP1786408A1 EP05771627A EP05771627A EP1786408A1 EP 1786408 A1 EP1786408 A1 EP 1786408A1 EP 05771627 A EP05771627 A EP 05771627A EP 05771627 A EP05771627 A EP 05771627A EP 1786408 A1 EP1786408 A1 EP 1786408A1
Authority
EP
European Patent Office
Prior art keywords
testosterone
hypogonadism
syndrome
deficiency
estrogen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05771627A
Other languages
English (en)
French (fr)
Other versions
EP1786408A4 (de
Inventor
Taru Blom
Janne Komi
Risto Lammintausta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hormos Medical Ltd
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/fi
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of EP1786408A1 publication Critical patent/EP1786408A1/de
Publication of EP1786408A4 publication Critical patent/EP1786408A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Definitions

  • This invention relates to a method for treatment or prevention of androgen deficiency in a male individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator (SERM).
  • SERM selective estrogen receptor modulator
  • the invention concerns further methods for treatment or prevention of diseases or disorders caused by said androgen deficiency.
  • Masculine sex hormones are responsible for the development of the masculine sex characteristics. Furthermore, they are required for reproduction.
  • the main element of the androgens is testosterone, which is imperative for the development and the function of the internal and external masculine sex organs, which has a supportive influence regarding muscle growth, which determines the distribution and the density of hair growth, which has a positive influence with respect to the production of erythrocytes and with respect to the distribution of erythropoietin and the cognitive functions.
  • a shortage of testosterone may be classified into two principle forms, which are designated primary and secondary hypogonadism. Diseases based on testosterone shortage include for instance osteoporosis, muscle atrophy, senescence outfall symptoms,

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05771627A 2004-09-03 2005-07-20 Verwendung eines selektiven östrogenrezeptormodulators zur herstellung eines pharmazeutischen präparates zur verwendung in einem verfahren für die behandlung oder vorbeugung von androgenmangel Withdrawn EP1786408A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
FI20041216A FI20041216A0 (fi) 2004-09-21 2004-09-21 Menetelmä androgeenivajeen hoitoon tai estoon
PCT/FI2005/000333 WO2006024689A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Publications (2)

Publication Number Publication Date
EP1786408A1 true EP1786408A1 (de) 2007-05-23
EP1786408A4 EP1786408A4 (de) 2010-07-28

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05771627A Withdrawn EP1786408A4 (de) 2004-09-03 2005-07-20 Verwendung eines selektiven östrogenrezeptormodulators zur herstellung eines pharmazeutischen präparates zur verwendung in einem verfahren für die behandlung oder vorbeugung von androgenmangel

Country Status (10)

Country Link
EP (1) EP1786408A4 (de)
JP (1) JP2008511615A (de)
KR (1) KR20070059110A (de)
AU (1) AU2005279178A1 (de)
BR (1) BRPI0514701A (de)
CA (1) CA2578852A1 (de)
MX (1) MX2007002606A (de)
NO (1) NO20071160L (de)
RU (1) RU2007112114A (de)
WO (1) WO2006024689A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5363344B2 (ja) 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
EP3205648A1 (de) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Östrogenrezeptormodulatoren und verwendungen davon
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
JP6697467B2 (ja) 2014-12-29 2020-05-20 オロン エス．ピー．エー． オスペミフェン及びフィスペミフェンを調製するためのプロセス
WO2023175010A1 (fr) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Utilisation du bazedoxifene pour augmenter la survie musculaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036360A1 (en) * 1999-11-16 2001-05-25 Hormos Medical Corporation Triphenylalkene derivatives and their use as selective estrogen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
JP2003534375A (ja) * 2000-05-26 2003-11-18 フィッチ，ハリー 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
EA200400744A1 (ru) * 2001-11-29 2005-02-24 Джи Ти Икс, ИНК. Предупреждение и лечение остеопороза, вызванного депривацией андрогенов

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036360A1 (en) * 1999-11-16 2001-05-25 Hormos Medical Corporation Triphenylalkene derivatives and their use as selective estrogen receptor modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUSCHEK ERIK J J ET AL: "Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men" EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 150, no. 4, April 2004 (2004-04), pages 539-546, XP002586475 ISSN: 0804-4643 *
See also references of WO2006024689A1 *
STEINER MITCHELL S ET AL: "Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia." CLINICAL PROSTATE CANCER JUN 2003 LNKD- PUBMED:15046680, vol. 2, no. 1, June 2003 (2003-06), pages 24-31, XP009134590 ISSN: 1540-0352 *

Also Published As

Publication number Publication date
MX2007002606A (es) 2007-05-15
JP2008511615A (ja) 2008-04-17
BRPI0514701A (pt) 2008-06-24
RU2007112114A (ru) 2008-10-10
KR20070059110A (ko) 2007-06-11
EP1786408A4 (de) 2010-07-28
CA2578852A1 (en) 2006-03-09
AU2005279178A1 (en) 2006-03-09
WO2006024689A1 (en) 2006-03-09
NO20071160L (no) 2007-05-25

Similar Documents

Publication Publication Date Title
Begam et al. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review
Komm et al. An overview of current and emerging SERMs
EP1786408A1 (de) Verwendung eines selektiven östrogenrezeptormodulators zur herstellung eines pharmazeutischen präparates zur verwendung in einem verfahren für die behandlung oder vorbeugung von androgenmangel
EP2106212B1 (de) Nuklearrezeptor-bindende wirkstoffe
Suh et al. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer
US9561238B2 (en) Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
FI118755B (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
KR101403893B1 (ko) 4,17β-디히드록시안드로스트-4-엔-3-온에 대한 신규한 용도들
US20060293294A1 (en) Method for treatment or prevention of androgen deficiency
EP2819676B1 (de) Kombinationstherapie zur behandlung von androgenmangel
CA2841572C (en) Trans-clomiphene metabolites and uses thereof
JP2003534375A (ja) 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
Bojkova et al. Metformin in chemically-induced mammary carcinogenesis in rats
JP6025301B2 (ja) 治療上の使用のためのｃ−１９ステロイド
Clarke et al. New selective estrogen and androgen receptor modulators
Wardley FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA
CN1168448C (zh) 预防和/或治疗乳腺癌的含类固醇芳香酶抑制剂的药物
CN1893955A (zh) 用于预防和治疗激素依赖性疾病的包含孕酮受体拮抗剂和纯抗雌激素的组合物
JP2001505574A (ja) １７α−ジヒドロエキレニンを使用した神経退化および認識機能障害の予防方法
Levin Fulvestrant
Kumar et al. Antiestrogen therapy for Breast Cancer: An overview.
US20230210870A1 (en) Methods of treating female health conditions related to sex hormones
Buzdar Hormonal therapy in early and advanced breast cancer
Zitzmann LONGTERM-TREATMENT OF OVERWEIGHT OR OBESE HYPOGONADAL MEN USING INTRAMUSCULAR TESTOSTERONE UNDECANOATE: EXPERIENCE OF 4-7 YEARS
Poirier et al. Chemical synthesis, plasmatic concentration and antisulfatase activity in mice and rats of a tetrahydroisoquinoline derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070306

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOMI, JANNE

Inventor name: BLOM, TARU

Inventor name: LAMMINTAUSTA, RISTO

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/085 20060101AFI20100615BHEP

Ipc: A61K 31/10 20060101ALI20100615BHEP

Ipc: A61P 5/32 20060101ALI20100615BHEP

Ipc: A61K 31/135 20060101ALI20100615BHEP

Ipc: A61K 31/395 20060101ALI20100615BHEP

Ipc: A61K 31/4164 20060101ALI20100615BHEP

Ipc: A61P 5/26 20060101ALI20100615BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100628

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110126